US Stock MarketDetailed Quotes

QNCX Quince Therapeutics

Watchlist

1.930
+0.180+10.29%

Close Dec 27 16:00 ET

1.840
-0.090-4.66%

Post 20:01 ET

84.92MMarket Cap-1.56P/E (TTM)

Quince Therapeutics Stock Forum

Highlyfavoured

Nov 21 21:55

$Quince Therapeutics (QNCX.US)$ slowly🥳

HailTheApocalypse

Nov 14 19:25

$Quince Therapeutics (QNCX.US)$ has some insanely target prices 😂. next year some time?

Quince Therapeutics(QNCX) Post-Mkt Price 1.900 0.00%

Learn. Trade. Win: Dive into our Global Paper Trading Challenge now!

Highlyfavoured

Nov 8 22:58

$Quince Therapeutics (QNCX.US)$
No reverse split! Moving up🙏🏻lookinh forward to next week!

Highlyfavoured

Nov 1 02:40

$Quince Therapeutics (QNCX.US)$ finally awake! lets break 1.7🙏🏻

WeiTheSaint469

Oct 30 09:27

in 1.316

$Quince Therapeutics (QNCX.US)$

Stock_Drift

Oct 24 13:20

Unusual Volume Ticks. 2:18pm

$Nukkleus (NUKK.US)$ $Fly-E (FLYE.US)$ $QuantumScape (QS.US)$ $Laird Superfood (LSF.US)$ $CCSC Technology International (CCTG.US)$ $Aligos Therapeutics (ALGS.US)$ $PureCycle Technologies (PCT.US)$ $Linkage Global (LGCB.US)$ $Quince Therapeutics (QNCX.US)$ $1847 Holdings (EFSH.US)$ $Nexalin Technology (NXL.US)$ $Nxu Inc (NXU.US)$ $Monopar Therapeutics (MNPR.US)$
📊⚡️📊

Jaguar8

Aug 15 07:55

NEWS

$Quince Therapeutics (QNCX.US)$
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Quince Therapeutics (Nasdaq: QNCX) announced the publication of Phase 3 ATTeST clinical trial data in The Lancet Neurology, evaluating EryDex for treating Ataxia-Telangiectasia (A-T). The study, involving 175 participants across 22 institutions in 12 countries, demonstrated a favorable safety pro...